Potentiation of cholinergic tone by pyridostigmine bromide re-instates and potentiates the growth hormone responsiveness to intermittent administration of growth hormone-releasing factor in man.

No abstract is available for this paper.

• Publication year

  1986

• Venue

  Acta Endocrinologica

• Publication date

  1986-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1530/ACTA.0.1130012PMID 3020850
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Growth hormone-releasing factor desensitization in rat anterior pituitary cells in vitro.

  1985cited by this paper
• Growth hormone releasing factor infusion does not sustain elevated GH-levels in normal subjects.

  1984cited by this paper
• Blockade of hp-GRF-40-induced GH release in normal men by a cholinergic muscarinic antagonist.

  1984cited by this paper
• Plasma growth hormone responses to constant infusions of human pancreatic growth hormone releasing factor. Intermittent secretion or response attenuation.

  1984cited by this paper
• The interrelationship of growth hormone (GH)-releasing factor and somatostatin in generation of the ultradian rhythm of GH secretion.

  1984cited by this paper
• Pituitary growth hormone response in rats during a 24-hour infusion of growth hormone-releasing factor.

  1984cited by this paper
• The effects of growth hormone (GH)-releasing peptides on GH secretion in perifused pituitary cells of adult male rats.

  1984cited by this paper
• Human pancreatic growth-hormone-releasing factor selectively stimulates growth-hormone secretion in man.

  1983cited by this paper
• Human pancreatic growth hormone-releasing factor-40 (hpGRF-40) allows stimulation of GH release by TRH.

  1983cited by this paper
• A noninvasive functional lesion of the hypothalamo-pituitary axis for the study of growth hormone-releasing factor.

  1983cited by this paper
• Influence of synthetic somatostatin upon growth hormone release from perifused rat pituitaries.

  1976cited by this paper

• Double Stimulation with Arginine Infusion for Assessment of Growth Hormone in Short Children

  2018cites this paper
• Donepezil May Reduce Insulin-Like Growth Factor-1 (IGF-1) Levels in Alzheimer's disease.

  2016cites this paper
• The GH-releasing effect of acylated ghrelin in normal subjects is refractory to GH acute auto-feedback but is inhibited after short-term GH administration inducing IGF1 increase.

  2013cites this paper
• Involvement of Brain Catecholamines and Acetylcholine in Growth Hormone Deficiency States

  2012cites this paper
• Involvement of Brain Catecholamines and Acetylcholine in Growth Hormone Hypersecretory States

  2012cites this paper
• Cholinergic and glutamergic receptor functional regulation in long-term, low dose somatotropin and insulin treatment to ageing rats: rejuvenation of brain function.

  2010cites this paper
• Mutation analysis of the muscarinic cholinergic receptor genes in isolated growth hormone deficiency type IB.

  2009cites this paper
• Muscarinic M1 and M3 Receptors,IP3 and cGMP Functional Regulation in Streptozotocin Induced Diabetic Rats: Insulin and Somatotropin Induced Rejuvenation as a Function of Age

  2008cites this paper
• Growth hormone, arginine and exercise

  2008cites this paper
• Oral arginine attenuates the growth hormone response to resistance exercise.

  2006cites this paper
• Perfil de secreção de hormônio de crescimento e ghrelina antes e após cirurgia bariátrica

  2005cites this paper
• The age-related down-regulation of the growth hormone/insulin-like growth factor-1 axis in the elderly male is reversed considerably by donepezil, a drug for Alzheimer's disease.

  2005cites this paper
• Dual Growth Hormone (GH) Response to Repeated GH Releasing Hormone Stimulus in Children and Adults

  2004cites this paper
• Effects of long-term estrogen replacement therapy on growth hormone response to pyridostigmine in healthy postmenopausal women.

  2003cites this paper
• The Reduced Release of GH by GHRH in 8 Subjects Aged 65–69 Years Is Augmented Considerably by Rivastigmine, a Drug for Alzheimer’s Disease

  2003cites this paper
• Prolonged treatment with glycerophosphocholine, an acetylcholine precursor, does not disclose the potentiating effect of cholinesterase inhibitors on GHRH-induced somatotroph secretion in anorexia nervosa

  2003cites this paper
• Effect of withdrawal of somatostatin plus GH‐releasing hormone as a stimulus of GH secretion in obesity

  2002cites this paper
• Growth hormone disturbances in adolescents with type 1 (insulin-dependent) diabetes mellitus : differentiating the GH signal

  2002cites this paper
• Complete inhibition of hypothalamic somatostatin activity is only partially responsible for the growth hormone response to strenuous exercise.

  2002cites this paper
• Update on Endocrine Disturbances in Anorexia Nervosa

  2001cites this paper
• The negative GH auto-feedback in childhood: Effects of rhGH and/or GHRH on the somatotroph response to GHRH or hexarelin, a peptidyl GH secretagogue, in children

  2000cites this paper
• Cholinergic modulation of growth hormone responses to growth hormone‐releasing hormone in uraemic patients on peritoneal dialysis

  2000influential citation
• Growth Hormone and Adipocyte Function in Obesity

  2000cites this paper
• Involvement of muscarinic cholinergic and α2-adrenergic mechanisms in growth hormone secretion during exercise in humans

  2000cites this paper
• Neuroregulation of Growth Hormone During Exercise in Children

  2000cites this paper
• Effects of cholinergic muscarinic blockade on growth hormone responses to growth hormone-releasing hormone in uraemic patients.

  1999cites this paper
• Age-related blunting of growth hormone secretion during exercise may not be soley due to increased somatostatin tone.

  1999cites this paper
• Neuroendocrine control of growth hormone secretion.

  1999cites this paper
• Effect of growth hormone-releasing peptide 1-6 on GH secretion-stimulated by GHRH and pyridostigmine in lambs.

  1998cites this paper
• Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human.

  1998cites this paper
• Reduced growth hormone (GH) responsiveness to combined GH‐releasing hormone and pyridostigmine administration in the Prader–Willi syndrome

  1998cites this paper
• Effect of acute pharmacological reduction of plasma free fatty acids on growth hormone (GH) releasing hormone-induced GH secretion in obese adults with and without hypopituitarism.

  1998cites this paper
• Growth hormone responses to growth hormone-releasing hormone and hexarelin in fed and fasted dogs: effect of somatostatin infusion or pretreatment with pirenzepine.

  1998cites this paper
• Effects of beta-adrenergic agonists and antagonists on the growth hormone response to growth hormone-releasing hormone in anorexia nervosa.

  1998cites this paper
• Repeated Administration of Growth Hormone-Releasing Hormone With or Without Previous Administration of Pyridostigmine in Insulin-Dependent Diabetes Mellitus

  1997cites this paper
• Mechanisms underlying the negative growth hormone (GH) autofeedback on the GH-releasing effect of hexarelin in man.

  1997cites this paper
• Pyridostigmine treatment selectively amplifies the mass of GH secreted per burst without altering GH burst frequency, half-life, basal GH secretion or the orderliness of GH release.

  1997cites this paper
• Effects of arginine, growth hormone-releasing hormone (GHRH) and neostigmine administered singly or in paired combinations on growth hormone (GH) release in pigs.

  1997cites this paper
• Influence of endogenous cholinergic tone and growth hormone‐releasing peptide‐6 on exercise induced growth hormone release

  1997cites this paper
• Effect of chronic treatment with biosynthetic growth hormone (GH) on the GH response to double GH-releasing hormone administration in children with short stature

  1997cites this paper
• Pre- and postprandial pyridostigmine and oxiracetam effects on growth hormone secretion in anorexia nervosa.

  1996cites this paper
• Acute administration of recombinant human growth hormone inhibits the somatotrope responsiveness to growth hormone-releasing hormone in childhood.

  1996cites this paper
• The effect of repeated administration of hexarelin, a growth hormone releasing peptide, and growth hormone releasing hormone on growth hormone responsivity

  1996cites this paper
• Aspects of the neuroendocrine control of somatotropic function in calorically restricted dogs and patients with eating disorders: studies with cholinergic drugs.

  1996cites this paper
• Acipimox-mediated plasma free fatty acid depression per se stimulates growth hormone (GH) secretion in normal subjects and potentiates the response to other GH-releasing stimuli.

  1996cites this paper
• Endogenous growth hormone (GH)-releasing hormone is required for GH responses to pharmacological stimuli.

  1996cites this paper
• Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression.

  1996cites this paper
• GH responsiveness to repeated GHRH or hexarelin administration in normal adults

  1995cites this paper
• Effect of combined administration of growth hormone (GH)-releasing hormone, GH-releasing peptide-6, and pyridostigmine in normal and obese subjects.

  1995cites this paper
• Acipimox potentiates growth hormone (GH) response to GH-releasing hormone with or without pyridostigmine by lowering serum free fatty acid in normal and obese subjects.

  1995cites this paper
• Effect of arginine and pyridostigmine on the GHRH-induced GH rise in obesity and Cushing's syndrome.

  1995cites this paper
• Effect of Pyridostigmine on the Hydrocortisone-Mediated Decrease of Circulating Growth Hormone Levels in Acromegaly

  1994cites this paper
• Interaction of salbutamol with pyridostigmine and arginine on both basal and GHRH‐stimulated GH secretion in humans

  1994cites this paper
• Acute effects of a single administration of dexamethasone on basal and growth hormone‐releasing hormone stimulated GH secretion in acromegaly

  1994cites this paper
• Effects of an Acetylcholine Precursor on GH Secretion in Elderly Subjects

  1994cites this paper
• Effects of oral glucose administration on spontaneous and growth hormone (GH)-releasing hormone-stimulated GH release in children and adults.

  1994cites this paper
• Arginine but not pyridostigmine, a cholinesterase inhibitor, enhances the GHRH-induced GH rise in patients with anorexia nervosa.

  1994cites this paper
• Lack of involvement of the cholinergic mechanism in vasoactive intestinal peptide- and peptide-histidine methionine-induced growth hormone (GH) responses in acromegaly: comparison with the GH responses to thyrotropin-releasing hormone and GH-releasing hormone.

  1994cites this paper
• Effect of pyridostigmine on the hydrocortisone-mediated decrease of circulating growth hormone levels in acromegaly.

  1994cites this paper
• Reduced growth hormone response to L-dopa and pyridostigmine in obesity.

  1994cites this paper
• Radiation and neuroregulatory control of growth hormone secretion

  1994cites this paper
• Effect of pyridostigmine on the growth hormone response to growth hormone-releasing hormone in lean and obese type II Diabetic patients.

  1994cites this paper
• Growth hormone response to L-dopa and pyridostigmine in women with polycystic ovarian syndrome.

  1993cites this paper
• Pyridostigmine potentiates growth hormone (GH)-releasing hormone-induced GH release in both men and women.

  1993cites this paper
• Eptastigmine augments basal and GHRH-stimulated growth hormone release in young and old dogs.

  1993cites this paper
• Elevated growth hormone responses to pyridostigmine in obsessive-compulsive disorder: evidence of cholinergic supersensitivity.

  1993cites this paper
• Melatonin stimulates growth hormone secretion through pathways other than the growth hormone‐releasing hormone

  1993cites this paper
• Galanin infusion partially restores the blunted growth hormone responses to repeated growth hormone releasing hormone stimuli in normal adults

  1993cites this paper
• Evidence against depletion of the growth hormone (GH)-releasable pool in human primary hypothyroidism: studies with GH-releasing hormone, pyridostigmine, and arginine.

  1993cites this paper
• Different effects of pyridostigmine on growth hormone (GH) response to GH-releasing hormone in endogenous and exogenous hypercortisolemic patients.

  1993cites this paper
• Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity.

  1993cites this paper
• Growth hormone secretion in Alzheimer's disease: studies with growth hormone-releasing hormone alone and combined with pyridostigmine or arginine.

  1993cites this paper
• Cholinergic control of growth hormone (GH) responses to GH‐releasing hormone in insulin dependent diabetics: evidence for attenuated hypothalamic somatostatinergic tone and decreased GH autofeedback

  1993cites this paper
• Pyridostigmine Effects on TSH Response to TRH in Adult and Children Obese Subjects

  1993cites this paper
• Regulation of Growth Hormone Secretion by the Growth Hormone Releasing Hexapeptide (GHRP-6)

  1993cites this paper
• Effects of administration of growth hormone-releasing factor to sows during late gestation on growth hormone secretion, reproductive traits, and performance of progeny from birth to 100 kilograms live weight.

  1992cites this paper
• GH response to GHRH, insulin, clonidine and arginine after GHRH pretreatment in children.

  1992cites this paper
• Effect of Enhancement of Cholinergic Tone on the Growth Hormone Response to Acute Hyperglycaemia or Thyrotropin‐Releasing Hormone in Dogs

  1992cites this paper
• Galanin reinstates the growth hormone response to repeated growth hormone‐releasing hormone administration in man

  1992cites this paper
• The effect of changing somatostatin tone on the pituitary growth hormone and thyroid-stimulating hormone responses to their respective releasing factor stimuli.

  1992cites this paper
• Differential effects of arginine on growth hormone releasing hormone and insulin induced growth hormone secretion

  1992cites this paper
• Cholinergic modulation of GH secretion in acromegalic patients before and after pituitary surgery.

  1992cites this paper
• Treatment of acromegaly with dopamine agonists.

  1992cites this paper
• Chapter 2 – Endocrine functions of the hypothalamus and alterations in neuroendocrine function – focus on thyrotropin and growth hormone

  1992cites this paper
• A neuroendocrinological approach to evidence an impairment of central cholinergic function in aging

  1992cites this paper
• Endocrine functions of the hypothalamus and alterations in neuroendocrine function--focus on thyrotropin and growth hormone.

  1992cites this paper
• The Effect of Endogenous Somatostatin Upon Human Thyrotrophin (TSH) Secretion

  1992cites this paper
• Pyridostigmine-mediated growth hormone release: evidence for somatostatin involvement.

  1992cites this paper
• Alpha-Glycerylphosphorylcholine Administration Increases the GH Responses to GHRH of Young and Elderly Subjects

  1992cites this paper
• Pyridostigmine-induced growth hormone responses in healthy and depressed subjects: evidence for cholinergic supersensitivity in depression

  1992cites this paper
• Influence of pyridostigmine on growth hormone (GH) response to GH-releasing hormone pre- and postprandially in normal and obese subjects.

  1992cites this paper
• Effect of potentiation of cholinergic tone by pyridostigmine on the GH response to GHRH in elderly men.

  1992cites this paper
• Application of pyridostigmine in evaluation of growth hormone reserves in children and adolescents.

  1991cites this paper
• Effects of exogenous growth hormone pretreatment on the pituitary growth hormone response to growth hormone-releasing hormone alone or in combination with pyridostigmine in type I diabetic patients.

  1991cites this paper
• Involvement of brain catecholamines and acetylcholine in growth hormone hypersecretory states. Pathophysiological, diagnostic and therapeutic implications.

  1991cites this paper
• Sexual dimorphism of pyridostigmine potentiation of growth hormone (GH)-releasing hormone-induced GH release in humans.

  1991cites this paper
• The late growth hormone rise induced by oral glucose is enhanced by cholinergic stimulation with pyridostigmine in normal subjects

  1991cites this paper
• Evidence that alpha 2-adrenergic pathways play a major role in growth hormone (GH) neuroregulation: alpha 2-adrenergic agonism counteracts the inhibitory effect of muscarinic cholinergic receptor blockade on the GH response to GH-releasing hormone, while alpha 2-adrenergic blockade diminishes the po

  1991cites this paper
• Gender and age differences in the growth hormone response to pyridostigmine.

  1991cites this paper
• Studies of growth hormone secretion in calorically restricted dogs: effect of cholinergic agonists and antagonists, glucose and thyrotropin-releasing hormone.

  1991cites this paper